The LYCRA Company Goes “ALL IN” at Intertextile Shanghai
1.9.2025 19:00:00 CEST | Business Wire | Press Release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, returns to Intertextile Shanghai (Sept. 2–4) with an exclusive global sneak preview of its latest denim innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250901230542/en/
The LYCRA Company makes a bold statement at Intertextile Shanghai with its open-concept pavilion showcasing the new ALL IN LYCRA® brand positioning.
For the first time, the company’s booth features an open-concept co-creation space designed to foster collaboration. Four key industry partners will join The LYCRA Company in this shared exhibit space, located in Hall 4.1 (Booth E56).This area is part of a larger 788-square-meter pavilion, which also includes 18 co-exhibitors. The impactful and visually striking design brings the new ALL IN LYCRA® brand positioning to life, creating an immersive experience for visitors.
ALL IN embodies what sets the LYCRA® brand apart – empowering customers in three critical ways:
- Delivering differentiated fibers that create high-performance products.
- Granting access to LYCRA® Labs and scientists committed to innovation and problem-solving.
- Offering compelling joint storytelling through tailored joint marketing programs.
This new positioning highlights the company’s commitment to helping partners stay competitive with advanced fiber solutions that enhance their products' capabilities.
“Intertextile Shanghai is the perfect platform to demonstrate how we’re going ‘ALL IN’ with our customers,” said Jason Wang, vice president - Asia, at The LYCRA Company. “We designed our exhibit space to foster deeper collaboration and stronger partnerships while showcasing our innovative, market-relevant solutions.”
Visitors to The LYCRA Company’s booth can explore the following innovations firsthand:
- LYCRA® VintageFX denimtechnology – Delivers vintage looks in low-stretch fabrics, combining lasting comfort and fit with heritage style.
- Bio-derived LYCRA® EcoMade fiber – Made from a renewable feedstock, this drop-in solution is expected to deliver the same performance as original LYCRA® fiber when it launches this year.
- LYCRA FitSense® denim technology – Adds targeted shaping and lift zones to denim without extra panels or seams for a customized fit.
- COOLMAX® EcoMade fiber – Made from 100% textile waste or recycled PET, its moisture-wicking, quick-drying performance benefits are demonstrated with an interactive display.
- THERMOLITE® EcoMade fiber – Uses 100% recycled materials to add lightweight warmth to a range of performance apparel.
The four partners in the open pavilion showcase LYCRA® fiber across the value chain—from yarn to finished garments:
- Lianxingfa is expanding the range of applications for LYCRA® ADAPTIV fiber, while Shining showcases its performance differentiation; both offer visitors an immersive experience.
- Trend Textilepresents sustainable knits made with LYCRA® FiT400™ fiber.
- Narik highlights seamless garments powered by LYCRA® fiber.
Guest speakers from denim partners will join representatives of The LYCRA Company in two presentations on September 3,highlighting our collaboration and ALL IN approach:
- LYCRA® VintageFX denim technology with Advance Denim and Texhong
- COOLMAX® fiber with SEAZON Denim
For more details on The LYCRA Company’s presence and activities at Intertextile Shanghai, visit its official event page.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA FitSense®, LYCRA® FiT400™, COOLMAX®, and THERMOLITE® are trademarks of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250901230542/en/
Contacts
Karie J. Ford
Karie.J.Ford@lycra.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom